OpportunityAnalyzer: Hodgkin’s Lymphoma (HL) – Global Drug Forecast and Market Analysis to 2024
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Hodgkin's lymphoma (HL), or Hodgkin's disease, is a malignancy which involves the lymph nodes and the lymphatic system. HL is a relatively rare type of cancer, accounting for 12% of all lymphomas and 0.6% of all new cancer cases, but overall prognosis is very good. However, treatment options for those patients who have failed first-line treatment are very few, and a significant unmet medical need remains in those patients. GlobalData estimated the HL market in the 7MM was valued at $316m in 2014. The HL market will increase approximately four-fold over the forecast period, reaching $1.4 billion by 2024 at a CAGR of 16%. This growth will be driven by label extensions for Adcetris (brentuximab vedotin), which is poised to enter earlier lines of HL therapy, as well as the approval and uptake of premium-priced products, such as the immune checkpoint inhibitors, Opdivo (nivolumab) and Keytruda (pembrolizumab). By the end of the forecast period, GlobalData expects Adcetris to retain and extend its lead as the HL market front-runner, with Opdivo and Keytruda making up a significant amount of the market. GlobalData anticipates that pipeline agents will have to show an efficacy advantage over currently used and inexpensive standard of care therapies. The challenge for new entrants in the HL market is to meet the high unmet need of relapsed or refractory (R/R) HL patients, reduce the long-term toxic side effects of current treatments, and improve overall survival.
Scope
Overview of HL, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
Top-line HL therapeutics market revenue from 2014–2024. Average cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the HL market.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
Analysis of the current and future market competition in the global HL market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key Highlights
Over the last forty years, only one targeted therapy has been approved for the treatment of HL — Adcetris. The HL space is now filled with excitement because Adcetris label extensions and approval of the first anti-PD-1 therapies are expected to change the treatment landscape. What will be the impact of these newly approved drugs on HL sales?
With the success of molecular-targeted therapies, including immune checkpoint inhibitors, across the oncology therapy area, what R&D strategies are being leveraged by companies to remain competitive in the HL space?
The survival of R/R HL patients remains poor, especially for those who fail transplant therapies. Therefore, there are considerably high unmet needs within this indication. What are the main unmet needs remaining in this space? Will the drugs under development fulfil the unmet needs of the HL market?
Acetylon Pharmaceuticals
Actinium Pharmaceuticals
ADC Therapeutics
Affimed Therapeutics
Amgen
Aptose Biosciences
Bayer Schering Pharma
Bellicum Pharmaceuticals
Bristol-Myers Squibb
Cell Medica Limited
Cellular Biomedicine Group
Constellation Pharmaceuticals
Curis
Eddingpharm
Gamida Cell
Incyte Corporation
Johnson & Johnson
Kyowa Hakki Kirin
Linus Oncology
Medarex
Menarini
Merck & Co.
Millennium Pharmaceuticals
Mirati Therapeutics
NantKwest
Novartis
Ono Pharmaceutical
Pfizer
Seattle Genetics
Syndax Pharmaceuticals
Takeda
Teva
TG Therapeutics
Yakult Honsha
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.